The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Combining T-cell engagers with conventional therapies to enhance responses in multiple myeloma
Diana Cirstea, MD, Massachusetts Cancer Center, Boston, MA, comments on the potential of combining T-cell engagers with conventional therapies to enhance responses in multiple myeloma. She highlights that this approach can increase response rates to 80-90% in heavily pretreated patients, with a relatively mild incidence of adverse events. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What we learned through ongoing trials and through the cumulative data that we see from trials that have been presented here at the IMS is that by combining bispecifics that already showed, right, this about 60% response rate in heavily pretreated patients, by combining those with other conventional therapies, we can build up on that and increase the response rate up to 80-90%. And because the incidence and the grade of the CRS and ICANS is relatively mild, it wouldn’t be an impediment in using these therapies combined with conventional therapies earlier in the treatment of myeloma...
What we learned through ongoing trials and through the cumulative data that we see from trials that have been presented here at the IMS is that by combining bispecifics that already showed, right, this about 60% response rate in heavily pretreated patients, by combining those with other conventional therapies, we can build up on that and increase the response rate up to 80-90%. And because the incidence and the grade of the CRS and ICANS is relatively mild, it wouldn’t be an impediment in using these therapies combined with conventional therapies earlier in the treatment of myeloma. It seems like a win and it seems like a very promising approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
